Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca Asthma Drug Fails Late-Stage Trials

AstraZeneca and its MedImmune division announced two Phase III trials of tralokinumab for severe, uncontrolled asthma failed to meet their primary endpoints.

Read More »

Allergan tries to assuage shareholder fears over Restasis

Allergan Plc tried to reassure shareholders after losing a major patent ruling during October 2017 on its second-most important drug, the dry-eye treatment Restasis, downplaying the importance of the loss of revenue from the drug.

Read More »

Novo Nordisk warns of U.S. legislation

Drugmaker Novo Nordisk warned that draft legislation in some U.S. states to make pricing more transparent could impact business in the company’s largest market.

Read More »

FDA Panel Backs Indivior’s Opioid Addiction Drug

The U.S. FDA’s Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 18-to-1 to recommend Indivior’s RBP-6000 to treat opioid use disorder.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom